Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013
MOUNTAIN VIEW, Calif., March 6, 2013
MOUNTAIN VIEW, Calif., March 6, 2013 /PRNewswire/ --Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) will report results for its fiscal year ended December 31,
2012, on Tuesday, March 26, 2013, following the close of the U.S. financial
markets. On Tuesday, March 26, 2013, at 5:00 p.m. Eastern Time / 2:00 p.m.
Pacific Time, the Company will host an investor conference call and live
webcast to provide a company update and discuss the financial results. The
conference call, live webcast and archived replay are open to all interested
To access the conference call via the Internet, go to www.alexza.com, under
the "Investor Relations" link. Please join the call at least 15 minutes prior
to the start of the call to ensure time for any software downloads that may be
required. Interested parties may also pre-register to avoid pre-call delays
at https://www.theconferencingservice.com/prereg/key.process?key= PV9FTPNLQ.
To access the live conference call via phone, dial 888-679-8035.
International callers may access the live call by dialing +1-617-213-4848.
The reference number to enter the call is 99281086.
The replay of the conference call may be accessed via the Internet, at
www.alexza.com, or via phone at 888-286-8010 for domestic callers or
+1-617-801-6888 for international callers. The reference number for the
replay of the call is 44796025. A replay of the call will be available for
two weeks following the event.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions, including agitation, acute repetitive
seizures and insomnia. Alexza's products are based on the Staccato® system, a
hand-held inhaler that is designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset with ease and
convenience for patients.
ADASUVE® (Staccato loxapine) is Alexza's first approved product, which was
approved by the U.S. Food and Drug Administration in December 2012 and by the
European Medicines Agency in February 2013. Grupo Ferrer Internacional, S.A.
is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia
and the Commonwealth of Independent States countries. The commercial launch
of ADASUVE is planned for the third quarter 2013 in the U.S. and Europe.
For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit www.alexza.com. For more
information about ADASUVE, please visit www.adasuve.com.
ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals,
Safe Harbor Statement
The anticipated news release and conference call will contain forward-looking
statements that involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a forward-looking
statement, as defined in the Private Securities Litigation Reform Act of 1995,
and should be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability for Alexza and
Ferrer to effectively and profitably commercialize ADASUVE, the adequacy of
the Company's capital to support the Company's operations, and the Company's
ability to raise additional funds and the potential terms of such potential
financings. The Company's forward-looking statements also involve assumptions
that, if they prove incorrect, would cause its results to differ materially
from those expressed or implied by such forward-looking statements. These and
other risks concerning Alexza's business are described in additional detail in
the Company's Annual Report on Form 10-K for the year ended December 31, 2011
and the Company's other Periodic and Current Reports filed with the Securities
and Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.
Contact: Karen L. Bergman, BCC Partners, +1-650-575-1509,
email@example.com or Michelle Corral, BCC Partners, +1-415-794-8662,
Press spacebar to pause and continue. Press esc to stop.